Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that SOCS3 treatment may effectively inhibit alopecia areata by suppressing CD8+ T cell activity and IFN-γ production.

This case study suggests that autoimmunity involving cytotoxic CD8+ T cells may link alopecia areata and human T-cell lymphotropic virus-1-associated myelopathy in adult T-cell leukemia/lymphoma patients.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

This review describes various T-cell-mediated alopecias characterized by distinct lymphocytic patterns and explores their pathophysiology. It highlights the role of CD8+ and regulatory T cells, the JAK/STAT pathway, and stem cell niches, contributing to understanding and potentially addressing these hair loss conditions.

This study identified keratins as autoantigens in alopecia areata and found that a tolerogenic form of keratin application delayed disease progression in mice by affecting T-cell responses.

This review discusses how urban air pollutants may influence the regulation of JAK3 signaling in alopecia areata and reports no new experimental results; the authors integrate existing data to map potential pathways and biomarkers.

In this study, researchers using a Treg-specific HuR-deficient mouse model found that the RNA-binding protein HuR is crucial for stabilizing Foxp3 mRNA, affecting Treg function and immune regulation, with HuR disruption leading to impaired Foxp3 expression and potential autoimmune dysfunction.

This study developed a technique to limit genetic recombination to regulatory T cells to investigate whether self-tolerance is maintained in non-lymphoid tissues, an area previously not well understood.

This article discusses alopecia areata as a potential model for studying T cell-dependent autoimmune diseases and reports no new experimental findings.

This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

This case report suggests that frontal fibrosing alopecia with nail involvement may be associated with lichen planus and improved with oral dutasteride due to an inflammatory reaction related to androgenetic alopecia.

This review discusses the clinical features, diagnosis, and treatment options for alopecia areata of the beard and reports no new clinical results.

This study reports that a 14-year-old female rhesus monkey with alopecia universalis was found to have a T-cell-mediated autoimmune disease similar to human alopecia areata universalis.

This case report describes the first dermoscopic evaluation of alopecia areata-like disease in a dog, where the condition mirrored human cases in terms of clinical presentation and treatment response.

In this study, a 55-year-old man with a localized patch of alopecia areata achieved hair regrowth through intralesional triamcinolone acetonide injections, demonstrating this treatment as an effective initial therapy for localized alopecia areata.

This case report illustrates that fibrosing alopecia in a pattern distribution may be misdiagnosed as androgenetic alopecia due to similar hair loss patterns, but distinctive trichoscopic and histopathologic features help differentiate it.

This article reviews the characteristics and presentation of fibrosing alopecia in a pattern distribution, a form of scarring alopecia similar to androgenetic alopecia and lichen planopilaris, but provides no new clinical findings.

This case report describes a young adult female with late-stage Vogt-Koyanagi-Harada disease featuring panuveitis, retinal detachment, hearing loss, alopecia, and vitiligo, who was successfully treated in a hospital.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This article reviews the autoimmune mechanism and potential environmental triggers of alopecia areata, focusing on cytokines, but does not provide new research findings.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study found that 363 genes were differentially expressed in alopecia areata skin compared to non-lesional skin, suggesting T-cell mediated immune responses and distinct gene profiles related to the disease's stage.

This review discusses the potential influence of gut microbiota on alopecia areata and suggests fecal microbial transplantation as a possible therapeutic approach but reports no new results.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

This report describes a case where an elderly woman developed alopecia areata shortly after receiving the Pfizer COVID-19 vaccine, which was effectively treated with topical tacrolimus and minoxidil.

ITK inhibitors may effectively treat alopecia areata.

This review highlights how chronic inflammatory skin disorders like psoriasis and atopic dermatitis may be better understood as manifestations of systemic immune dysregulation rather than just skin issues, suggesting that recognizing these conditions as markers of broader immune imbalance can improve diagnosis and medical education.